Shares of GRIFOLS S A/S (NASDAQ:GRFS) have been assigned an average recommendation of “Hold” from the eight research firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, three have assigned a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $20.75.

A number of equities analysts recently commented on the stock. JPMorgan Chase & Co. upgraded shares of GRIFOLS S A/S from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $21.00 to $22.50 in a research note on Thursday, June 27th. BidaskClub upgraded shares of GRIFOLS S A/S from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 3rd. Zacks Investment Research upgraded shares of GRIFOLS S A/S from a “sell” rating to a “hold” rating in a research note on Thursday. Finally, ValuEngine downgraded shares of GRIFOLS S A/S from a “hold” rating to a “sell” rating in a research note on Thursday, August 1st.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in shares of GRIFOLS S A/S by 9.1% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,296 shares of the biotechnology company’s stock worth $127,000 after buying an additional 526 shares during the period. Wetherby Asset Management Inc. boosted its stake in shares of GRIFOLS S A/S by 5.5% during the second quarter. Wetherby Asset Management Inc. now owns 16,189 shares of the biotechnology company’s stock worth $342,000 after buying an additional 849 shares during the period. Advisors Asset Management Inc. boosted its stake in shares of GRIFOLS S A/S by 40.8% during the first quarter. Advisors Asset Management Inc. now owns 5,108 shares of the biotechnology company’s stock worth $103,000 after buying an additional 1,479 shares during the period. Lenox Wealth Management Inc. boosted its stake in shares of GRIFOLS S A/S by 0.7% during the first quarter. Lenox Wealth Management Inc. now owns 236,947 shares of the biotechnology company’s stock worth $4,765,000 after buying an additional 1,652 shares during the period. Finally, Bank of Montreal Can boosted its stake in shares of GRIFOLS S A/S by 2.3% during the first quarter. Bank of Montreal Can now owns 89,850 shares of the biotechnology company’s stock worth $1,807,000 after buying an additional 2,017 shares during the period. Institutional investors own 19.14% of the company’s stock.

Shares of GRFS stock traded down $0.02 on Thursday, reaching $21.82. 527,700 shares of the stock were exchanged, compared to its average volume of 1,116,347. The company has a quick ratio of 0.95, a current ratio of 2.68 and a debt-to-equity ratio of 1.38. The company’s 50 day moving average price is $21.83. The stock has a market cap of $15.02 billion, a P/E ratio of 18.65, a price-to-earnings-growth ratio of 1.34 and a beta of 1.11. GRIFOLS S A/S has a twelve month low of $17.42 and a twelve month high of $23.03.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

Featured Story: Guidelines for Successful Channel Trading

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.